Logo for Camurus

Camurus Investor Relations Material

Latest events

Logo for Camurus

Q1 2024

Camurus
Logo for Camurus

Q1 2024

8 May, 2024
Logo for Camurus

Q4 2023

15 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Camurus

Access all reports
Segment Data
Access more data
Revenue by
Products and services
Product sale
Sales of development-related goods and services
Licensing revenues and milestone payment
Expenses by
Financials
Camurus AB is a pharmaceutical company developing and commercializing medicines for severe and chronic conditions. Camurus AB's product portfolio includes PRADAXA, which is indicated for the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; TYSABRI for multiple sclerosis (MS) and psoriatic arthritis; DIFICID for antibiotic-associated diarrhea (AAD); EURAX for ulcerative colitis; and ORAPAVAN for nephrotic syndrome. Camurus AB is based in Lund, Sweden.